FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.
The GLP-3 (R) peptide is a synthetic multi-receptor research peptide studied for a single defining property: it is designed to engage three related receptors at once, the GLP-1 and GIP incretin receptors and the glucagon receptor. That breadth of receptor engagement is what distinguishes it from the single- and dual-receptor peptides in the same research series.
This article describes the structure of GLP-3 (R), the triple-receptor pharmacology it is studied for, how it sits within the broader incretin-receptor research series in the catalog, and how the material is verified.
Research Snapshot
- GLP-3 (R) is a synthetic peptide analog with the molecular formula C221H342N46O68 and a molecular weight of approximately 4,731.33 g/mol, carrying defined structural modifications for extended stability in experimental systems.
- It is studied as a triple-receptor agonist, engaging the GLP-1 and GIP incretin receptors and the glucagon receptor, in defined in vitro receptor-binding research.
- It sits at the top of a receptor-breadth series in the catalog: single-receptor, amylin-class, dual-receptor, and triple-receptor analogs, which together let researchers compare how receptor engagement scales.
- Incretin receptors are G-protein-coupled receptors, and multi-receptor peptides are studied as tools for probing how simultaneous engagement of more than one receptor behaves relative to single-receptor engagement (Campbell & Drucker, 2013).
- Pure Health Peptides supplies GLP-3 (R) as a lyophilized Vial, part of the wider catalog. Every lot is finished and tested in the US, routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner.
Introduction
The incretin receptors are a small family of related G-protein-coupled receptors, and much of the recent research interest in synthetic peptide analogs has moved from engaging one of them to engaging several at once. A peptide that binds a single receptor is one kind of research tool; a peptide engineered to bind two or three is a different kind, useful precisely because it lets researchers study what changes when receptor engagement broadens.
GLP-3 (R) is the broadest of these in the catalog.
This article stays with the molecule and the preclinical research built on it: its structure, the triple-receptor pharmacology it is designed for, its place in a graded series of single- to triple-receptor analogs, and the verification chain underneath the material.
It describes findings in preclinical and in vitro receptor-research terms throughout, with no extension to applied use.
The GLP-3 (R) Peptide: A Triple-Receptor Agonist
GLP-3 (R) is a synthetic peptide of approximately 4,731.33 g/mol (molecular formula C221H342N46O68), built with structural modifications that support stability in experimental systems. Its defining feature is not its size but its target profile: it is designed to act as an agonist at three receptors simultaneously, the GLP-1 receptor, the GIP receptor, and the glucagon receptor.
Engineering a single peptide to engage three related but distinct receptors is a significant design problem, because each receptor recognizes a different region and geometry. GLP-3 (R) is the catalog’s example of a peptide built to that specification, which makes it a defined tool for triple-receptor research.
As a synthetic sequence with a specified composition, its identity is confirmed against its certificate of analysis, the basis of lot-level verification.
The Incretin Receptor Research Series
GLP-3 (R) is best understood as the widest point of a graded series, and the series is what makes the catalog useful for comparative receptor research. At the single-receptor end sits GLP-1 (S), a GLP-1 receptor agonist. Alongside it is GLP-1 (C), an amylin-class analog that engages a different receptor system, and the two are also offered together as the GLP-1 (C/S) blend. Stepping up in receptor breadth, GLP-2 (T) is a dual agonist engaging two receptors, and GLP-3 (R) completes the progression as the triple agonist.
Laid out this way, single to dual to triple, the series is a compact research toolkit for studying how receptor engagement scales, with each analog a defined point of comparison. Every one is supplied as a lyophilized vial, and each is a distinct pharmacological tool rather than a substitute for another.
Why Multi-Receptor Agonists Are Studied
The research rationale for a peptide like GLP-3 (R) is comparison. These receptors share a family relationship as class B GPCRs but signal through their own routes, and a central question in receptor pharmacology is how simultaneous engagement of several receptors compares with engaging one (Campbell & Drucker, 2013; Müller et al., 2019). A graded set of single-, dual-, and triple-receptor analogs gives researchers exactly the reference points needed to study that question under controlled in vitro conditions.
That is the appropriate framing for GLP-3 (R): a receptor-pharmacology research tool defined by the breadth of its receptor engagement, studied in preclinical and in vitro systems, with the described work confined to receptor binding and signaling rather than any applied outcome.
Verification
Underneath the compound is the verification chain. Pure Health Peptides does not manufacture the material; production is sourced from qualified third-party manufacturers, and the material is finished and tested in the US. Every lot is routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner, and each qualified lot’s Certificate of Analysis is published in the COA Library, in the vial section, retrievable by batch ID. For a lyophilized vialed peptide the appropriate panel extends beyond identity, purity, and quantity to include endotoxin and microbial limits, because contamination can enter downstream of synthesis through handling, lyophilization, vial filling, storage, and transit. The Testing Process page documents how that verification runs, and the Manufacturing Process page covers where the material comes from. The guide to reading a Certificate of Analysis walks through the panel field by field.
Where GLP-3 (R) Sits in Incretin Receptor Research
For researchers studying incretin-receptor pharmacology, GLP-3 (R) is a specific and well-defined tool: a synthetic peptide built to engage three receptors at once, sitting at the top of a graded single-to-triple series. Its research value rests on that receptor breadth and on the comparison it enables against the narrower analogs beside it.
As research on multi-receptor peptides continues, a defined triple agonist remains a valuable reference compound, and GLP-3 (R) holds a clear place at the head of the incretin-receptor series in the catalog.
Frequently Asked Questions
What is the GLP-3 (R) peptide?
GLP-3 (R) is a synthetic multi-receptor research peptide (molecular formula C221H342N46O68, molecular weight approximately 4,731.33 g/mol) designed to engage three related receptors: the GLP-1 and GIP incretin receptors and the glucagon receptor.
What is GLP-3 (R) studied for in research?
It is studied as a triple incretin-receptor agonist in defined in vitro receptor-binding research, as a tool for examining how engaging three related receptors at once compares with single-receptor engagement.
How does GLP-3 (R) relate to GLP-1 (S), GLP-1 (C), and GLP-2 (T)?
They form a graded receptor-breadth series: GLP-1 (S) is a single GLP-1 receptor agonist, GLP-1 (C) is an amylin-class analog, GLP-2 (T) is a dual-receptor agonist, and GLP-3 (R) is the triple-receptor agonist at the top of the series.
Why are multi-receptor peptides studied?
Because a central question in incretin-receptor pharmacology is how simultaneous engagement of several receptors compares with engaging one. A graded set of analogs provides defined reference points for that comparison in vitro.
What carrier format is GLP-3 (R) available in, and how is it verified?
A lyophilized vial. Every lot is finished and tested in the US and routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics, with a lot-specific Certificate of Analysis published in the COA Library.
References
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism, 2013;17(6):819-837. https://doi.org/10.1016/j.cmet.2013.04.008
- Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 2019;30:72-130. https://doi.org/10.1016/j.molmet.2019.09.010
- Gribble FM, Reimann F. Metabolic messengers: the incretin hormones. Nature Metabolism, 2021. https://pubmed.ncbi.nlm.nih.gov/33767443/
- International Organization for Standardization / International Electrotechnical Commission. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html
